Omniscope

Founded 2020
Employees 10+
Primary contact
Parc Científic de Barcelona, Cluster II - Floor 3
Avenida Doctor Marañon, 8
08028 Barcelona
Catalonia
Spain
Diseases & Conditions
Omniscope has developed an AI-enabled platform to perform high-precision immune profiling, which is the process of understanding why people respond differently to viruses, to inform research, diagnostics, and therapeutic development. The company's OS-T technology allows mapping of a complete T cell response, up to 1 million T cells per clinical sample. Its other offering, OS-IP, is browsable immune portal that lets researchers identify biomarkers with intuitive data analysis. Also, Omniscope is working on different products in immunotherapy (OS-IMT), vaccine development (OS-VAX) and patient monitoring (OS-MRD). Aside from its Barcelona headquarters, the company has offices in Malta and Palo Alto, California.
Founded 2020
Employees 10+
Primary contact
Parc Científic de Barcelona, Cluster II - Floor 3
Avenida Doctor Marañon, 8
08028 Barcelona
Catalonia
Spain
Diseases & Conditions

Funding 💰

Total €3.9M
Select investors European Commission, Malta Enterprise, Vedra Partners, Plug and Play

Key people 🧑‍🤝‍🧑

Highlights

  • Universal diagnostic tool: Omniscope's revolutionary universal diagnostic tool allows researchers to read the immune system through simple, non-invasive clinical tests (like a blood test), which means that everyone, everywhere can benefit from this innovation in disease detection and diagnosis.
  • Transforming tech: Omniscope's technology can identify the root cause of diseases, enabling precise diagnoses and efficient and curative therapeutic intervention. Its disruptive tools have the potential to transform today's "modern" medicine from treating symptomatic patients to avoiding symptomatic progression entirely. The implications for personal well-being, public health, and even longevity are huge.
  • Applications: The company's technology provides a holistic view of immune system dynamics to inform vaccine development (OS-VAX), measure therapy efficacy (OS-IMT), and for hematological malignancies detect early traces of disease (OS-MRD).

Video ▶️

Last update: June 3, 2023